During this roundtable, more than 2,000 companies applied for funding and only 99 candidates were selected to receive funding out of a total of € 627 million of EIC funds available. Following a rigorous selection process, BELKIN Vision was not only one of the 99 winners but also one of the 19% of companies headed by a woman CEO. Applicants must meet the EIC criteria of excellence, impact and level of risk, and by the time they reach the final selection stage, they are considered to be world-class, high-impact innovations.
To date, BELKIN Vision has raised $ 19 million through investors and is also a former beneficiary of the EU’s Horizon 2020 program, which has helped the company reach many critical milestones, including the completion of its pivotal multi-center clinical trial, the results of which are expected in 2022. The additional funds will be used to begin commercialization and grow the business at a significantly higher rate, initially by Europe then globally in order to provide glaucoma care accessible to all. The company anticipates a controlled deployment in Europe end of 2022.
BELKIN’s vision protection technology could revolutionize the treatment of glaucoma for the 140 million people with glaucoma and ocular hypertension worldwide. The treatment is contactless, automated and easy for any ophthalmologist to administer in seconds. The economic impact on health is significant and should allow better access to high quality glaucoma treatment.
CEO, Daria lemann blumenthal said, “We couldn’t be happier to have been selected to receive EIC funding. This EU validation will help us continue to advance our technology, enabling us to bring to market a treatment for glaucoma that will have a significant impact on population health and prevention of blindness worldwide. We are grateful for the support of the EIC and look forward to a successful partnership.
About BELKIN Vision:
BELKIN Vision is an Israeli medical device company, established in 2013, developing an intuitive, automated and rapid glaucoma laser treatment aimed at promoting accessibility to primary care for gout-free glaucoma by enabling any ophthalmologist to treat a lot more patients in any location. Visit the BELKIN Vision website to find out more.
BELKIN Vision LinkedIn
BELKIN Vision YouTube
For press images, please visit our Dropbox
Media contact: Nancy Le Bosquain, director of communications, 613-606-8003, [email protected]
Photo – https://mma.prnewswire.com/media/1713106/BELKIN_Vision_In_Use_2_photo_courtesy_of_Yosee_Letova.jpg
SOURCE BELKIN Vision Ltd.